Impact of smoking history on postoperative complications after lung cancer surgery – a study based on 286 cases

Mateusz Kozub¹, Bartosz Gachewicz¹, Mariusz Kasprzyk¹, Magdalena Roszak², Lukasz Gasiorowski³, Wojciech Dyszkiewicz¹

¹Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland
²Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland

Kardiochirurgia i Torakochirurgia Polska 2019; 16 (1): 13-18

Abstract

Aim: The aim of the study was to evaluate the impact of smoking cessation and its timing in the preoperative period on postoperative morbidity in patients undergoing surgery for non-small cell lung cancer (NSCLC).

Material and methods: Two hundred and eighty-six patients surgically treated for NSCLC were prospectively analyzed in terms of duration and intensity of smoking, time period from smoking cessation to surgery, and postoperative morbidity. The patients were divided into five groups: I – current smokers and past smokers who quit smoking less than 2 weeks before surgery (n = 67), II – past smokers who quit 2 weeks to 3 months (n = 106), III – past smokers who quit 3 months to 1 year (n = 30), IV – past smokers who quit more than 1 year (n = 71), V – never smokers (n = 12).

Results: In the analyzed group 95.8% were smokers or past smokers. Postoperative complications occurred in 40.2% of patients including pulmonary (21.3%) and cardiac morbidity (17.8%). The pulmonary and circulatory morbidity rates were the lowest in group V but the differences were not significant. Similarly, there were no significant differences between groups with and without pulmonary or circulatory complications regarding: number of daily smoked cigarettes, smoking duration and the moment of cessation. The analysis of segmental regression showed the smallest percentage of complications in patients who quit smoking between the 8th and the 10th week before the operation.

Conclusions: Among patients surgically treated for NSCLC, duration of smoking and number of smoked cigarettes has no significant influence on frequency and type of postoperative complications. The best moment to quit smoking is the period between the 8th and the 10th week preceding surgery.

Key words: lung cancer, smoking history, postoperative complications.

Streszczenie

Cel: Celem pracy była ocena wpływu palenia tytoniu i momentu zaprzestania palenia na częstość występowania i rodzaj powikłań pooperacyjnych u chorych leczonych chirurgicznie z powodu niedrobnokomórkowego raka płuc (NDRP).

Materiał i metody: W badaniu obejmującym grupę 286 chorych na NDRP analizie poddano czas trwania palenia, liczbę wypalanych papierosów, czas od momentu zaprzestania palenia do operacji oraz częstość występowania i rodzaj powikłań pooperacyjnych. Chorych podzielono na pięć grup: I – palący do momentu operacji lub pacjenci, którzy rzucili palenie w ostatnich 2 tygodniach przed operacją (n = 67), II – pacjenci, którzy zaprzestali palenia od 2 tygodni do 3 miesięcy przed zabiegiem (n = 106), III – osoby, które rzucili palenie od 3 miesięcy do roku przed operacją (n = 30), IV – pacjenci, którzy zaprzestali palenia więcej niż rok przed zabiegiem (n = 71), V – osoby, które nigdy nie palły (n = 12).

Wyniki: W badanej grupie 95,8% chorych było palaczami tytoniu. Powikłań pooperacyjnych wystąpiły u 40,2% chorych, w tym u 21,3% powikłań oddechowych i u 17,8% powikłań krążeniowych. Częstość występowania powikłań oddechowych i krążeniowych była najniższa w grupie V, ale różnice w odsetkach powikłań w poszczególnych grupach nie były istotne statystycznie. Również liczba wypalanych papierosów, czas palenia mierzony w paczkolatach oraz moment rzucenia palenia nie wpływały istotnie na częstość występowania powikłań. Poprzez analizę regresji segmentowej wykazano, że najmniejszy odsetek powikłań występuje u chorych rzucających palenie między 8. a 10. tygodniem przed planowaną operacją.

Wnioski: U chorych leczonych chirurgicznie z powodu NDRP czas palenia tytoniu oraz liczba wypalanych papierosów nie wpływają istotnie na częstość występowania i rodzaj powikłań pooperacyjnych. Najkorzystniejszym momentem na zaprzestanie palenia jest okres między 8. a 10. tygodniem poprzedzającym zabieg.

Słowa kluczowe: rak płuc, palenie tytoniu, powikłania pooperacyjne.

Address for correspondence: Dr. Mariusz Kasprzyk, Department of Thoracic Surgery, Poznan University of Medical Sciences, 62 Szamarzewskiego St, 60-569 Poznan, Poland, phone: +48 61 665 43 49, e-mail: kasprzykmariusz@hotmail.com

Received: 29.01.2019, accepted: 3.03.2019.
Introduction

Smoking is clearly documented as the most important etiological factor in the development of lung cancer. Eighty-ninety-four percent of patients suffering from lung cancer are smokers or past smokers with an average 30–50 pack-years of tobacco use [1-4]. Smoking may also increase pulmonary and circulatory morbidity after various types of surgery, which is caused by chronic bronchitis and atherosclerosis of coronary vessels induced by tobacco smoke. According to several authors, postoperative complications occur 1.4 to 4.3 times more frequently among smokers in comparison with non-smokers [4, 9, 10]. It seems that the most prone to morbidity are patients undergoing a lung cancer resection who did not quit smoking prior to surgery. The morbidity rate among surgically treated lung cancer patients varies between 10% and 50% in the case of lobectomy and 35% to 80% after pneumonectomy [6, 7]. The majority of clinicians are confident that smoking cessation causes undeniable health benefits and it is indicated at each stage of diagnosis and treatment regimens among patients with lung cancer [8]. On the other hand, there are inconsistent reports about the significance of smoking cessation in the short preoperative period, i.e. a few days or weeks before the planned surgical procedure [4, 9, 10]. Some reports even suggest a paradoxical increase in the pulmonary complication rate among patients who quit smoking just before surgery, and the authors of these reports recommend surgery deferral up to 8 weeks from the cessation if possible [9, 11].

Aim

The aim of this study was to evaluate the impact of smoking cessation and its moment in the preoperative period on frequency and type of postoperative complications in patients treated surgically due to non-small cell lung cancer (NSCLC).

Material and methods

Two hundred eighty-six patients surgically treated for NSCLC in 2010–2015 were analyzed in this study. Informed consent was obtained from each patient and the study was approved by the Ethics Committee. The history of smoking was obtained before the procedure using a self-report questionnaire. The data about surgical procedures and postoperative complications were collected from medical files of thoracic surgery, intensive care unit departments and outpatient clinics. The patients were divided into five groups depending on prior smoking history:

- group I – current smokers and past smokers who quit smoking less than 2 weeks before surgery (n = 67),
- group II – past smokers who quit 2 weeks to 3 months before surgery (n = 106),
- group III – past smokers who quit 3 months to 1 year before surgery (n = 30),
- group IV – past smokers who quit more than 1 year before surgery (n = 71),
- group V – lifelong non-smokers: patients who have never smoked (n = 12).

In preoperative functional assessment of the respiratory system and circulatory system the following tests were performed: pulmonary function tests, capillary blood gases, diffusing capacity of the lung for carbon monoxide (DLCO), 6-minute walk test, stair climb test, ECG, echocardiography. Surgical procedures were performed under general intravenous anesthesia with double-lumen intubation of the right and left bronchi and through anterolateral thoracotomy (n = 214) or VATS (video-assisted thoracoscopic surgery) (n = 72).

The following pulmonary complications were encountered: postoperative pneumonia, atelectasis that required fiberoptic bronchoscopy, respiratory failure with prolonged mechanical ventilation or need for reintubation, pulmonary embolism, prolonged air leak more than 5 days, residual pneumothorax and bronchopleural fistula.

Myocardial infarction, cardiac arrhythmias and hypotonia with need for catecholamine infusion were defined as cardiac complications.

All complications occurred during postoperative hospitalization or up to 30 days after surgery.

Statistical analysis

Statistical analysis was conducted using Statistica 10 software (TIBCO Software Inc. Palo Alto, CA, USA). Mann-Whitney U test, $\chi^2$ test with Yates correction, Spearman test and segment regression test were used. For all tests the statistical significance level was set at $p = 0.05$.

Results

There were 198 men and 88 women aged 29 to 81 (average age 63) in the analyzed group of patients. Two hundred and four patients underwent lobectomy, 36 pneumonectomy, 33 bilobectomy and 13 wedge resection. Histopathological examination revealed squamous cell carcinoma in 150 cases, adenocarcinoma in 111 cases, giant cell carcinoma in 20 cases and carcinoid in 5 cases. The cancer staging system followed the 7th edition of the TNM classification (UICC 2009). In 58.4% of patients there were no metastases in regional lymph nodes, in 26.6% metastases in N1 lymph nodes were observed and in 15% N2 disease was confirmed. Neoadjuvant (induction) chemotherapy was used in a group of 14 patients (4.9%). Table I shows demographic and clinical data of the analyzed population.

Among 286 analyzed patients 274 (95.8%) were smokers or past smokers. Only 12 (4.2%) were lifelong non-smokers. Two hundred and thirty-two (81.1%) patients quit smoking before surgery, including 164 less than 1 year before surgery (1–40 weeks, mean: 9 weeks). Sixty-eight patients discontinued smoking more than a year before surgery (1–30 years, mean: 9.8 years). Data of smoking history are presented in Table II.

In groups of current smokers and past smokers (groups I, II, III, IV) the majority were male. In the group of lifelong non-smokers (group V) the number of men and women was equal. The average age was the lowest in group V.
The average age of patients was 63 years, with the highest age in group IV (66 years) and the highest in group I (61 years). The lowest average amount of pack-years was observed in group IV (32.9) whereas the highest was in group II (39.4). The shortest total duration of smoking was noted in group IV (average 36 years) whereas the longest was in group III (average 46 years). Squamous cell cancer constituted the majority in all groups of smokers (groups I, II, III, IV) whereas in group V adenocarcinoma was most frequently confirmed. The most frequent surgical procedure in each group was lobectomy.

Complications during the postoperative period occurred in 115 (40.2%) patients. Pulmonary complications occurred in 61 (21.3%) patients, circulatory in 51 (17.8%) and other complications in 19 (6.6%). Types and rates of individual complications are presented in Table III. Mann-Whitney U test showed no significant differences between groups with and without pulmonary complications, respectively in: number of smoked cigarettes per day ($p = 0.354$), duration of smoking ($p = 0.975$), pack-years ($p = 0.917$) and moment of smoking cessation ($p = 0.466$). Similarly, there were no significant differences between groups with and without circulatory complications, respectively in: number of daily smoked cigarettes ($p = 0.746$), duration of smoking ($p = 0.382$), pack-years ($p = 0.932$) and moment of smoking cessation ($p = 0.528$). Spearman rank correlation showed no significant relationship between circulatory morbidity and: number of smoked cigarettes ($p = 0.705$), duration

### Table I. Demographic and clinical data

| Parameter                                 | Value                      |
|-------------------------------------------|----------------------------|
| Age                                       | 29–81 years (mean: 63)     |
| Sex M/F                                   | 198 (69.2%)/88 (30.8%)     |
| Histological type:                        |                            |
| Squamous cell carcinoma                   | 150 (52.4%)                |
| Adenocarcinoma                            | 111 (38.8%)                |
| Giant-cell carcinoma                      | 20 (7%)                    |
| Carcinoid                                 | 5 (1.8%)                   |
| Surgical approach:                        |                            |
| Thoracotomy                               | 214 (74.8%)                |
| VATS                                      | 72 (25.2%)                 |
| Type of surgery:                          |                            |
| Lobectomy                                 | 204 (71.3%)                |
| Pneumonectomy                             | 36 (12.6%)                 |
| Bilobectomy                               | 33 (11.5%)                 |
| Wedge resection                           | 13 (4.6%)                  |
| Nodal status:                             |                            |
| pN0                                       | 167 (58.4%)                |
| pN1                                       | 76 (26.6%)                 |
| pN2                                       | 43 (15%)                   |
| pT:                                       |                            |
| T1                                        | 76 (26.6%)                 |
| T2                                        | 167 (58.4%)                |
| T3                                        | 41 (14.3%)                 |
| T4                                        | 2 (0.7%)                   |
| Comorbidities:                            |                            |
| COPD                                      | 94 (32.9%)                 |
| Arterial hypertension                     | 61 (21.3%)                 |
| Ischemic heart disease                    | 30 (10.5%)                 |
| Diabetes                                  | 26 (9.1%)                  |
| Previous myocardial infarction            | 11 (3.8%)                  |
| Arrhythmia                                | 10 (3.5%)                  |
| Chronic kidney disorder                   | 6 (2.1%)                   |
| Previous ischemic stroke                  | 4 (1.4%)                   |
| Other                                     | 12 (4.2%)                  |

### Table II. Smoking history data

| Parameter                                 | Value                      |
|-------------------------------------------|----------------------------|
| Smokers/never smokers                     | 274 (95.8%)/12 (4.2%)      |
| Duration of smoking                       | 1–60 years (mean: 37.5 years) |
| Number of smoked cigarettes per day       | 3–60 (mean: 22)            |
| Pack-years                                | 0.15–126 (mean: 36)        |
| Patients who quit smoking prior to procedure: |                        |
| Within 2 weeks                            | 13 (4.6%)                 |
| 2 weeks to 3 months                       | 106 (37.1%)               |
| 3 months to 1 year                        | 30 (10.5%)                |
| Over 1 year before operation              | 71 (24.8%)                |
| Still smoke cigarettes                    | 54 (18.9%)                |

### Table III. Postoperative complications

| Complication                                | Value |
|---------------------------------------------|-------|
| Pulmonary:                                  |       |
| Prolonged air leak                          | 25 (8.7%) |
| Atelectasis                                 | 16 (5.6%) |
| Residual pneumothorax                       | 11 (3.8%) |
| Bronchopleural fistula                      | 10 (3.5%) |
| Pneumonia                                   | 8 (2.8%)  |
| Respiratory failure                         | 7 (2.4%)  |
| Circulatory:                                |       |
| Atrial fibrillation                         | 47 (16.4%) |
| Hypotonia requiring catecholamine infusion  | 4 (1.4%)  |
| Myocardial infarction                       | 1 (0.4%)  |
| Other                                       |       |
| Wound infection                             | 5 (1.8%)  |
| Bleeding                                    | 3 (1.1%)  |
| Other                                       | 14 (4.9%) |

(61 years) and the highest in group IV (66 years). The lowest average amount of pack-years was observed in group IV (32.9) whereas the highest was in group II (39.4). The shortest total duration of smoking was noted in group IV (average 36 years) whereas the longest was in group III (average 46 years). Squamous cell cancer constituted the majority in all groups of smokers (groups I, II, III, IV) whereas in group V adenocarcinoma was most frequently confirmed. The most frequent surgical procedure in each group was lobectomy.
Impacts of smoking history on postoperative complications after lung cancer surgery – a study based on 286 cases

Table IV. Incidence of pulmonary and circulatory complications among individual groups of patients

| Complications     | Group I (n = 67) | Group II (n = 106) | Group III (n = 50) | Group IV (n = 71) | Group V (n = 12) | Overall (n = 286) |
|-------------------|------------------|--------------------|-------------------|------------------|-----------------|------------------|
| Total             | 20 (40.3%)       | 40 (37.7%)         | 10 (33.3%)        | 33 (46.5%)       | 5 (41.7%)       | 115 (40.2%)      |
| Pulmonary         | 16 (23.9%)       | 23 (21.7%)         | 4 (13.3%)         | 17 (23.9%)       | 1 (8.3%)        | 61 (21.3%)       |
| Circulatory       | 8 (11.9%)        | 20 (18.9%)         | 4 (13.3%)         | 18 (25.3%)       | 1 (8.3%)        | 51 (17.8%)       |

Table V. Incidence of complications in periods related to moment of smoking cessation before surgery

| Number of period | Time before operation (weeks) | Complication rate (%) |
|------------------|------------------------------|-----------------------|
| 1                | 0–2                          | 41                    |
| 2                | 1–3                          | 40                    |
| 3                | 2–4                          | 42                    |
| 4                | 3–5                          | 37                    |
| 5                | 4–6                          | 36                    |
| 6                | 5–7                          | 38                    |
| 7                | 6–8                          | 34                    |
| 8                | 7–9                          | 38                    |
| 9                | 8–10                         | 29                    |
| 10               | 9–11                         | 30                    |
| 11               | 10–12                        | 43                    |
| 12               | 11–52                        | 38                    |
| 13               | > 52                         | 43                    |

Discussion

Studies conducted on populations of patients who underwent various surgical procedures prove that smoking is, beside age, type of surgery, and coexistent diseases, a crucial factor related to increased postoperative complication rate [8, 9, 11, 12]. Mills et al. in a meta-analysis of 15 randomized studies and 6 observational studies confirmed a decrease in complication risk altogether, pulmonary complication risk and wound healing complication risk among patients who quit smoking before surgery [8]. The influence of tobacco smoking on occurrence of complications concerns mainly pulmonary complications, because long-term exposure to components of tobacco smoke contributes to an increase in the serum carboxyhemoglobin level, chronic bronchitis, dysfunction of ciliated epithelium, increase in thick secretion in the respiratory tree and dysfunction of macrophages in lungs, which reduces the efficiency of local defense mechanisms [12–14]. Patients suffering from lung cancer who are qualified for surgical treatment are particularly susceptible to pulmonary complications because 90% of them are long-term smokers and surgery involving resection of part or the whole lung leads to restriction of respiratory function. Moreover, long-term smoking is a frequent cause of coexistent COPD and ischaemic heart disease. Thirty-four percent of patients suffering from lung cancer are treated for COPD and 10% suffer from coronary artery disease [15–17]. In a prospective study conducted by Mason et al. including 7965 patients surg-
Among patients surgically treated for lung cancer the mortality among smokers or past smokers was 5 times higher than that among never smokers (1.5% vs. 0.3%) [18] even though in several other studies a significant difference in perioperative mortality between smokers and never smokers was not found [4, 6, 19]. Smoking cessation in the long term causes undeniable health benefits, but the impact of cessation in the period shortly before surgery on complication risk decrease is considered ambiguous among researchers. The majority of clinicians are convinced of the benefits caused by smoking cessation even in the immediate period before surgery. On the other hand, the authors of a few studies noted a paradoxical increase in complication rate among patients who quit smoking within a few weeks before surgery [9, 11, 18]. Myers explains this fact by an increase in thick secretion production and decrease in cough reflex directly after smoking cessation, which causes higher risk of atelectasis and postoperative pneumonia [20]. The question arises whether to advise smoking cessation in the group of long-term smokers shortly before surgery, exposing them to additional stress and in that case which moment to quit is the most beneficial considering potential complications. Bluman et al. analyzed a group of 410 patients who underwent surgical procedures in the field of general surgery, orthopedics, urology, cardiac surgery and vascular surgery, noting a higher pulmonary complication rate among current smokers in comparison to patients who quit at least 2 weeks before surgery and never smokers (22%, 12.8%, 4.9%, respectively). However, in the group of smokers there was noted 6.7 times greater risk of pulmonary complications among patients who reduced smoking immediately before surgery in comparison to the group continuing smoking up to the day of the operation. Patients who quit smoking within 4 weeks before surgery had a greater risk of pulmonary complications the closer the day of cessation was to the surgery [9]. Warner et al. recommend 8 weeks and Nakagawa et al. at least a 4-week period of smoking abstinence before surgery to lower the risk of pulmonary complications [11, 12]. Furthermore, Barrera et al. during analysis of 300 patients who underwent anatomical lung resection due to primary or secondary neoplasm did not observe an increase in pulmonary complication frequency in the group that quit smoking in the last 2 months before the surgical procedure. The pulmonary complication rate and postoperative pneumonia frequency were significantly lower in the group of never smokers in comparison to recent smokers and past smokers and the low value of postoperative predicted DLCO and smoking more than 60 pack-years were significant factors which increased the pulmonary complication risk [4]. Likewise, a meta-analysis conducted by Wong et al. including 25 studies (21 381 patients who underwent various types of surgery including thoracic surgery and cardiac surgery) proved greater relative risk of pulmonary complications among patients who smoked to the day of the operation in comparison to never smokers. The pulmonary complication risk among patients who quit smoking more than 4 weeks before surgery was significantly lower in comparison to patients who did not quit before the operation and in the case of more than 8 weeks of abstinence, risk was comparable to never smokers. The authors did not observe significant differences between groups of smokers and never smokers according to cardiovascular complications and the moment of cessation had no influence on risk of occurrence of these complications [21].

In our study, in the group of 286 patients surgically treated for NSCLC, duration of smoking as well as number of smoked cigarettes had no significant influence on the frequency of all complications or on incidence of either pulmonary or circulatory complications. Although the rate of pulmonary complications among never smokers was notably lower than among current smokers and past smokers (8.3% vs. 21.5%, respectively), the difference was not statistically significant. However, it should be underlined that there was a small number of never smokers in the study group (12 out of 286 patients), which could affect the results of statistical analysis. Similarly, Shimizu et al. in a group of 194 patients surgically treated for lung cancer did not observe significant relations between history of smoking and complication rate [22]. The authors explain the fact of a low postoperative complication rate among never smokers and smokers by more frequent detection of early stage lung tumors thanks to screening programs using a low-dose CT scan, which causes an increase in the rate of videothoracoscopic resections, regularly decreasing the number of pneumonectomies and extensive procedures as well as causing a noticeable improvement of perioperative care, effective COPD treatment, implementation of a respiratory rehabilitation program and precise functional assessment during qualification for surgery. In Barrera’s and Nakagawa’s previously cited studies, there were differences in the frequency of respiratory complications between the groups of smokers and non-smokers; however, similarly to our work, between individual subgroups of smokers separated according to the history of smoking such differences were not observed [4, 12]. Results of analysis conducted in our study confirm the opinions presented in the other studies that the preoperative time of smoking abstinence should be at least 8 weeks. Likewise in the present study segmental regression analysis of individual periods in the preoperative time proves that the most beneficial moment for smoking cessation is the time between 8 and 10 weeks before surgery. According to British recommendations, the latency time between the general physician’s suspicion of lung cancer and surgical treatment should not exceed 2 months. In Polish healthcare system conditions this period is 2 to 6.5 months [23]. This time should be effectively used to persuade patients to quit smoking from the beginning of the diagnostic process, which may lead to a decrease in postoperative complication risk.

Conclusions

Among patients surgically treated for NSCLC, duration of smoking and number of smoked cigarettes have no sig-
nificant influence on frequency and type of postoperative complications. Based on our analysis, we conclude that the best moment to quit smoking before the operation is the period between the 8th and the 10th week preceding surgery.

Disclosure

The authors report no conflict of interest.

References

1. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Cancer 2005; 92: 426-429.
2. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PI. Lung cancer in never smokers – a review. Eur J Cancer 2012; 48: 1299-1311.
3. Crispo A, Brennan P, Jöckel KH, Schaffrath-Rosario A, Wichmann HE, Nyberg F, Simonato L, Merletti F, Forastiere F, Boffetta P, Darby S. The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer 2004; 91: 1280-1286.
4. Barbera R, Shi W, Amar D, Thaler H, Gabovich N, Bains MS, White DA. Smoking and timing of cessation. Impact on pulmonary complications after thoracotomy. Chest 2005; 127: 1977-1983.
5. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340: 937-944.
6. Vaporciyan AA, Merriman KW, Ece F, Roth JA, Smythe WR, Swisher SG, Walsh GL, Nesbitt JC, Putnam JB Jr. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg 2002; 73: 420-425.
7. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, Inculet RJ, Jones DR, BF, Harpole DH, Putnam JB Jr, Rusch VW. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006; 81: 1013-1020.
8. Mills E, Eyawo O, Lockhart I, Phil D, Kelly S, Wu P, Ebbert JO. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med 2011; 124: 144-154.
9. Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest 1998; 113: 883-889.
10. Schmidt-Hansen M, Page R, Hasler E. The Effect of preoperative smoking cessation or preoperative pulmonary rehabilitation on outcomes after lung cancer surgery: a systematic review. Clin Lung Cancer 2013; 14: 96-102.
11. Warner MA, Offord KP, Warner ME, Lennon RL, Corover MA, Jansson-Schumacher U. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. Mayo Clin Proc 1989; 64: 609-616.
12. Nakagawa M, Tanaka H, Tsukuma H, Kishi Y; Clinical Investigations. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 2001; 120: 705-710.
13. Erskine RJ, Murphy PJ, Langton JA. Sensitivity of upper airway reflexes in cigarette smokers: effect of abstinence. Br J Anaesth 1994; 73: 298-302.
14. Kotani N, Hashimoto H, Sessler DI, Yatsu Y, Muraoka M. Exposure to cigarette smoke impairs alveolar macrophage functions during halothane and isoflurane anesthesia in rat. Anesthesiology 1999; 91: 1823-1833.
15. Jassem JM, Bobowiec M, Stomoríski JM, Jassem E. The incidence of chronic obstructive pulmonary disease in advanced nonsmall cell lung cancer patients. Adv Palliat Med 2007; 6: 99-102.
16. Jassem E. COPD, lung cancer – a common molecular pathway? Pneumonolog Pol 2013; 81: 283-284.
17. Dzyatkiewicz W, Jermielity M, Piwowski C, Perek B, Kasprzyk M. Simultaneous lung resection for cancer and myocardial revascularization without cardiopulmonary bypass (off-pump coronary artery bypass grafting). Ann Thorac Surg 2004; 77: 1023-1027.
18. Mason DP, Subramanian S, Nowicki ER, Grab JD, Murthy SC, Rice TW, Blackstone EH. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database Study. Ann Thorac Surg 2009; 88: 362-370.
19. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002; 359: 115-117.
20. Myers K, Hajek P, Hinds C, McRobbie H. Stopping smoking shortly before surgery and postoperative complications. Arch Intern Med 2011; 11: 983-989.
21. Wong J, Lam DP, Abrihami A, Cham MT, Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. J Can Anesth 2012; 59: 268-279.
22. Shimizu K, Nakata M, Hiramii Y, Maeda A, Tanemoto K. Recent results regarding the clinical impact of smoking history on postoperative complications in lung cancer patients. Interact Cardiovasc Thorac Surg 2008; 10: 1001-1006.
23. Fundacja Watch Health Care. Onkobarometr Fundacji Watch Health Care nr 6/1/02/2016. Korektor Zdrowia, Kraków 2016: 52.